Pentoxifylline Suppresses Transduction by HIV-1-Based Vectors

  title={Pentoxifylline Suppresses Transduction by HIV-1-Based Vectors},
  author={Johanna A. Smith and Giuseppe Nunnari and Mirjam A. R. Preuss and Roger J. Pomerantz and René Daniel},
  pages={377 - 386}
Pentoxifylline, a caffeine-related compound, was shown to suppress human immunodeficiency virus type 1 (HIV-1) replication. This effect is thought to be mediated by inhibition of tumor necrosis factor-alpha (TNFα)-mediated long-terminal repeat (LTR)-driven expression. We now demonstrate that pentoxifylline efficiently inhibits transduction by HIV-1-based vectors. This latter effect is independent of LTR-driven expression, and correlates with a reduced efficiency of the completion of the… 

Figures from this paper

Characterizing the antiviral effect of an ATR inhibitor on human immunodeficiency virus type 1 replication

It is proposed that ETP-46464 produces its inhibitory effect on HIV-1 replication by acting in both the early and late phases of the retroviral replication cycle.

Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors

An overview of the different strategies used to inhibit HIV transcription is given and the current repertoire of small molecular weight compounds that target HIV transcription are reviewed.

Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy?

The state of the art of compounds that target HIV accessory proteins is presented and promising compounds have been found within different classes of molecules: small natural and synthetic molecules, peptides and proteins, oligonucleotides, in particular those used as RNA interference (RNAi) tools.

A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19

PTX is a non-selective phosphodiesterase drug, that has anti-inflammatory and antioxidant effects thereby can reduce SARS-CoV-2 infection-hyperinflammation and oxidative stress and seems to be an effective agent against Covid-19 severity.

Sirtuin-1 and HIV-1: an overview.

The potential role of SIRT1 as a pharmacological target of HIV-1 replication is discussed and it is suggested that this mechanism leads to the hyperactivation of NF- κB proinflammatory pathway and may likely contribute to the chronic immune activation state of HIV -infected individuals.

Identification of SNF2h, a Chromatin-Remodeling Factor, as a Novel Binding Protein of Vpr of Human Immunodeficiency Virus Type 1

SNF2h, a chromatin-remodeling factor, is identified as a novel binding partner of Vpr involved in its chromatin recruitment and the role of DSB and DSB signals in the viral infection is discussed.

Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals.

HAART represents the first treatment in patients with moderate lesions limited to skin, and it can be sufficient to reduce significantly the size of lesions and, often, the complete disappear in 35% of cases after 3-9 months of treatment.

LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals.

Chronic inflammation, including residual viral replication, may contribute to hypovitaminosis D, by modulating vitamin D metabolism and catabolism.

Cryptococcal meningitis in an HIV-1-infected person: relapses or IRIS? Case report and review of the literature.

The case of an HIV-positive man, who developed cryptococcal meningitis two months after having started HAART and experienced several meningeal relapses and a "paradoxical" C-IRIS during the following year is presented.



Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action.

The inducibility of HIV-1 LTR-driven gene expression by PMA or TNF-alpha in transiently transfected cells was completely eliminated by point mutations in the NF-kappa B motifs, suggesting that NF- kappa B plays a major role in the activation of the HIV- 1 LTR by these agents in this cell system.

Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase

It is demonstrated that a novel and specific small molecule inhibitor of ATM kinase activity, KU-55933, is capable of suppressing the replication of both wild-type and drug-resistant HIV-1.

Pentoxifylline for the Treatment of HIV Infection and Its Complications

In a quality of life trial, PTX was associated with improvement in depression, anger, and social and cognitive function; a placebo effect, however, was not ruled out and further studies of HIV-infected persons are needed.

Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells.

It is concluded that patients with AIDS may benefit from pentoxifylline treatment because of its blockage of TNF-alpha-mediated HIV-1 upregulation, from increased efficacy of AZT, and also from improvement in TNF -alpha-induced cachexia.

Pentoxifylline for the treatment of infection with human immunodeficiency virus.

  • B. Dezube
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1994
Pentoxifylline, a trisubstituted xanthine derivative, has been used to decrease blood viscosity and is reasonably well tolerated by most recipients of the drug.

Pentoxifylline and Other Protein Kinase C Inhibitors Down-Regulate HIV-LTR NF-κB Induced Gene Expression

The mechanism of inhibitory action of PTX on virus replication and NF-κB-induced trans-activation of HIV-1 gene expression has been elucidated as due to blocking PKC-dependent PMA- or TNF-α-induced activation of NF-β in Jurkat and 293-27-2 cells.

Wortmannin Potentiates Integrase-Mediated Killing of Lymphocytes and Reduces the Efficiency of Stable Transduction by Retroviruses

The hypothesis that DNA repair proteins of the NHEJ pathway and, in their absence, ATM are required to avoid integrase-mediated 2killing and allow stable retroviral DNA transduction is supported.

Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.

It is demonstrated that inhibition of DHS by CNI-1493 or RNA interference efficiently suppressed the retroviral replication cycle in cell culture and primary cells and no measurable drug-induced adverse effects on cell cycle transition, apoptosis, and general cytotoxicity were observed.

Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-κB activation

The data suggest that the inhibitory effect of PTX on HIV replication cannot be satisfactorily explained by the inhibition of NF-κB or TNF-α, and PTX has several immunomodulatory and antiviral properties which could be of benefit against HIV-1 at various levels.